Ask AI
ProCE Banner Activity

Optimizing CKM Syndrome Care: Expert Answers to Your Frequently Asked Questions

Clinical Thought

Learn about specific considerations for managing cardiovascular–kidney–metabolic (CKM) syndrome and initiating guideline-directed medical therapy early in personalized treatment plans for patients with CKM conditions.

Released: April 29, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

Supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.

Boehringer Ingelheim Pharmaceuticals, Inc.

Eli Lilly and Company

Target Audience

This educational activity is intended for cardiology physicians, nurse practitioners, and physician associates who care for patients with HF and/or CKD (with or without diabetes).

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify persistent gaps in the care of patients with cardio-renal-metabolic disease and the clinical impact of delayed intervention

Faculty Disclosure

Primary Author

Stephen J. Greene, MD: researcher: AstraZeneca, Bayer, Boehringer Ingelheim, CSL Vifor, Merck, Novartis, Otsuka; consultant/advisor/speaker: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Corcept Therapeutics, Corteria, Idorsia, Lexicon, Lilly, Merck, Novo Nordisk, Otsuka, Roche Diagnostics, Sanofi, scPharmaceuticals, Sumitomo, Tricog Health, Viatris.